Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T4UL
|
||||
| Former ID |
DCL000591
|
||||
| Drug Name |
PD-348292
|
||||
| Synonyms |
Eribaxaban; PD 0348292; PD 348292; PD0348292; Eribaxaban (USAN); PD-0348292; N-(4-Chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Discontinued in Phase 2 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H22ClFN4O4
|
||||
| Canonical SMILES |
COC1CC(N(C1)C(=O)NC2=CC=C(C=C2)Cl)C(=O)NC3=C(C=C(C=C3)N<br />4C=CC=CC4=O)F
|
||||
| InChI |
1S/C24H22ClFN4O4/c1-34-18-13-21(30(14-18)24(33)27-16-7-5-15(25)6-8-16)23(32)28-20-10-9-17(12-19(20)26)29-11-3-2-4-22(29)31/h2-12,18,21H,13-14H2,1H3,(H,27,33)(H,28,32)/t18-,21-/m1/s1
|
||||
| InChIKey |
QQBKAVAGLMGMHI-WIYYLYMNSA-N
|
||||
| CAS Number |
CAS 536748-46-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Coagulation factor Xa | Target Info | Inhibitor | [2], [3] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Blood coagulation | ||||
| Pathway Interaction Database | Beta2 integrin cell surface interactions | ||||
| PathWhiz Pathway | Coagulation | ||||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | ||||
| Intrinsic Pathway of Fibrin Clot Formation | |||||
| Common Pathway of Fibrin Clot Formation | |||||
| Gamma-carboxylation of protein precursors | |||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Human Complement System | |||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
| Blood Clotting Cascade | |||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024432) | ||||
| REF 2 | Pfizer. Product Development Pipeline. March 31 2009. | ||||
| REF 3 | Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011 Apr;38 Suppl 1:S3-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.